Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dror Michaelson

Showing results (51-60 of 121) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone MetastasesRana R McKay, Dominick Bossé, Kathryn P Gray, et al.
British Journal of Cancer|October 23, 2015
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patientsFrede Donskov, M Dror Michaelson, Igor Puzanov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II StudyMichael B Atkins, Gwenaelle Gravis, Kazimierz Drosik, et al.
The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.
Targeted Oncology|April 1, 2017
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell CarcinomaBrian I Rini, Victor Gruenwald, Eric Jonasch, et al.
The Oncologist|May 7, 2022
Phase II Study of Cabozantinib in Patients With Bone MetastasisEdwin Choy, Gregory M Cote, M Dror Michaelson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 15, 2024
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancerPhilip J Saylor, Sergey V Kozin, Aya Matsui, et al.
Cancer|March 18, 2014
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinomaDavid Cella, Mellar P Davis, Sylvie Négrier, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2014
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigenMaha Hussain, Paul G Corn, M Dror Michaelson, et al.
Pageof 13

Showing results (51-60 of 121) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Radium-223 Dichloride in Combination with Vascular Endothelial Growth Factor-Targeting Therapy in Advanced Renal Cell Carcinoma with Bone MetastasesRana R McKay, Dominick Bossé, Kathryn P Gray, et al.
British Journal of Cancer|October 23, 2015
Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patientsFrede Donskov, M Dror Michaelson, Igor Puzanov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II StudyMichael B Atkins, Gwenaelle Gravis, Kazimierz Drosik, et al.
The Journal of Urology|September 18, 2007
Sunitinib efficacy against advanced renal cell carcinomaRobert J Motzer, M Dror Michaelson, Jonathan Rosenberg, et al.
Targeted Oncology|April 1, 2017
Long-term Duration of First-Line Axitinib Treatment in Advanced Renal Cell CarcinomaBrian I Rini, Victor Gruenwald, Eric Jonasch, et al.
The Oncologist|May 7, 2022
Phase II Study of Cabozantinib in Patients With Bone MetastasisEdwin Choy, Gregory M Cote, M Dror Michaelson, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 15, 2024
The radiopharmaceutical radium-223 has immunomodulatory effects in patients and facilitates anti-programmed death receptor-1 therapy in murine models of bone metastatic prostate cancerPhilip J Saylor, Sergey V Kozin, Aya Matsui, et al.
Cancer|March 18, 2014
Characterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinomaDavid Cella, Mellar P Davis, Sylvie Négrier, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapyGary R Hudes, Michael A Carducci, Toni K Choueiri, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2014
Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigenMaha Hussain, Paul G Corn, M Dror Michaelson, et al.
Pageof 13